AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$MOBI

Mobia Medical reports Q3 results (NASDAQ:MOBI)

Mobia Medical (MOBI) reported Q3 GAAP EPS of -$0.52 and revenue of $15.6M, up 73% Y/Y. The company raised its full-year 2026 revenue guidance to $57M-$57.5M from $54M-$56M, with $160.7M in cash as of September 30, 2026.

Original reporting
seekingalpha.com
Published Nov 6, 2026, 10:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$MOBI
Bullish
high confidence
Mentioned
$MOBI
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$MOBIBullishMed
01

Why it matters

The earnings beat on revenue and upward guidance could attract short‑covering and new buying.

02

Market read

Micro‑cap earnings with guidance lift; relevant for traders tracking small‑cap health‑tech stocks.

03

What to watch

Cash burn remains high and EPS is still negative; liquidity risk persists.

Relevance 7/10Novelty 8/10Timing: today

Background

Mobia Medical is a Nasdaq‑listed medical device company reporting its third‑quarter results.

Company-level read

Ticker impact

$MOBIBullishHigh confidence
Context

Mobia Medical disclosed Q3 GAAP EPS of -$0.52 and raised full-year 2026 revenue guidance to $57M-$57.5M.

Expected impact

upward pressure as investors price in higher revenue outlook

Evidence & confidence

Revenue grew 73% YoY and guidance was increased, indicating better-than-expected performance.

Market effects

Sector

Higher guidance may lift sentiment in the med‑tech/health‑services niche.

Regional

Limited to U.S. small‑cap investors focused on biotech and medical devices.

Global

Minimal; impact confined to niche investors.

Counterpoint

What could challenge this read

Guidance raise may be premature if Q4 results miss expectations.

Key entities

  • Company
    Mobia Medical, Inc.

    Issuer of the earnings release.

Read at source← All news

Related articles

$MOBIMed

What Mobia Medical (MOBI) Said on Its Q3 Earnings Call

Mobia Medical (MOBI) reported Q3 earnings with a net loss of $17.3M ($0.52 per share), improved from last year. Gross margin rose to 83.2%. Operating expenses increased to $31.5M due to higher personnel costs. The company cited positive impacts from revised stroke recovery guidelines and expects to publish clinical evidence in 2027.

finance.yahoo.com
$MOBIHigh

Mobia Medical Reports Third Quarter 2026 Financial Results

Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Third Quarter 2026 Financial Results Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance Austin, Texas, November 5, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke

SEC EDGAR 8-K
$MOBIHigh

Mobia Medical stock jumps on stroke guideline inclusion

Mobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.

investing.com
$MOBIMedAI 8/10

Mobia Medical (MOBI) Q2 2026 Earnings Call Transcript

Mobia Medical (MOBI) reported Q2 2026 revenue of $13.5M, up 102% YoY, driven by Vivistim system adoption. Full-year guidance set at $54M-$56M. Net loss was $21M, with cash reserves of $177.1M post-IPO. Management plans to expand active territories and target 1,500 U.S. stroke centers.

fool.com